Header and Body 2

Problem Addressed

Many cancer cells overexpress anti-apoptotic Bcl-2 family proteins that confer resistance to chemotherapy treatment. Selective inhibitors of Bcl-2 are available in clinic to treat Bcl-2 dependent cancers. However, such tools are missing for Bfl-1. Selective inhibitors allow for selective targeting of Bfl-1 dependent cancer cells while limiting systemic toxicity.